Solvias的动态

???Exploring Membrane Proteins in Drug Discovery??? Did you know that 60% of drug targets are membrane proteins? Despite their importance, they can be quite challenging to study. In our latest application note, we delve into how the SELECT SERIES Cyclic IMS instrument is lending a hand in this field by providing high-quality native MS data for membrane proteins. Read the application note here - https://lnkd.in/eqBKeUsA Key Highlights: - Efficient Micelle Removal:?The instrument’s declustering capabilities ensure high-quality spectral data for membrane proteins. - CCS Measurement:?Cyclic ion mobility enables CCS measurement, allowing us to track crucial structural changes. - Enhances Drug Discovery Workflows:?Enabling the detection and identification of candidate therapeutics. Returning to my native MS roots, I had the pleasure of collaborating with the talented team at OMass Therapeutics – Feng Qu, Kleitos Sokratous, Idlir Liko and Jonathan Hopper – to showcase the SELECT SERIES Cyclic IMS for these challenging analytes. #Teammassspec #pharma #membraneproteins #nativems #drugdiscovery

https://lnkd.in/eZ5mvU2N Pleased to be able to publish a short case-study on our internal drug discovery efforts against an important immuno-oncology target. What this case study demonstrates for me personally is that integrated discovery is more than the sum of its parts. When all disciplines are aligned and the work is put in at early stages to define optimal outcomes rapid and efficient progress of projects is achievable, even in difficult targets. Our goal is to advance our client projects towards the clinic with the shared aim of improving disease outcomes. We act as a partner and a critical-friend when required to get to key decision points as efficiently as possible. The potential patients at the end of the process deserve nothing less than drug discovery scientists to be relentless in our pursuit of compound quality and be as lean as possible in our hunt for drug candidates. Charnwood Discovery have a multitude of services which can be combined in an almost infinite number of ways, the skill is defining what package/cascade is most appropriate for the project in hand (This is not static and will develop with the project and the data). Our website details the services offered by our amazing scientists, however reaching out to discuss how we can apply these skills on your project is where the magic happens!

Pharmaron has participated in the development of 8 protein degraders currently in clinical trials, about 80 candidates currently in preclinical testing stages, and more than 100 ongoing projects to discover new molecules for targeted protein degradation. Our wealth of experience benefits our clients, who rely on Pharmaron to cover every step of the drug discovery process, from the preclinical phase to clinical testing. Learn more about the entire Protein Degrader Discovery Platform: Learn more about our Targeted Protein Degradation Services - https://lnkd.in/dghrFMHX #targetedproteindegradation #drugdiscovery #protac #proteindegradation #TPD #proteindegraders

With major collaborations and partnership deals involving companies like C4 Therapeutics, Inc. , Merck, Monte Rosa Therapeutics and more, and significant progress in the clinic with BTK degraders and other assets, it’s crucial to unite at the 7th TPD & Induced Proximity Summit taking place in Boston this October. The longest standing and most comprehensive protein degradation and proximity conference will span everything from foundational research and discovery to IND-filing and clinical trials, allowing a deep dive into the opportunities and challenges in expanding the target space and developing therapeutically relevant degraders, blockers, stabilisers, and inducers of protein-protein interactions. Uniting over 550 enthusiasts from across the field, we will be providing a comprehensive view of protein degradation and modulation research, including SureTACs, EpiTACs, RIPTACs, Molecular Gates, and more, allowing you to network with experts in the space, benchmark against competitors and stay ahead of the curve. ?? Interested in getting involved? Email me at [email protected] or message me via LinkedIn and I will be happy to share the agenda! #proteindegradation #TPD #targetedproteindegradation #inducedproximity #WomenInTPD #molecularglues #partnershipsinTPD

Researchers, how would you propose to progress drug delivery systems for the posterior inner eye segment? Your solutions should ensure sustained release over at least three months for diverse therapeutics ranging from low molecular weight compounds to complex molecules. Learn more on our open science platform #opnMe: https://lnkd.in/gEDjfkdd

The field of targeted protein degradation is truly changing the face of small molecule drug discovery. This emerging therapeutic approach has the potential to drastically affect patient outcomes. Learn more about TPD and how it can provide new avenues for drug discovery. Learn more in our latest blog: https://lnkd.in/e6EgrxBu #biosynth #PROTAC #LYTAC #AbTAC #smallmolecules #drugdiscovery

Today, we announced a significant milestone in our collaboration with Eli Lilly and Company. Lilly has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis (ALS) identified and validated by our AI-enabled CONVERGE? platform. Read more about our partnership and the predictive power of CONVERGE? to prioritize targets validated in disease-relevant models at significantly higher rates than industry standards.?https://lnkd.in/gkZ3z2zZ #DrugDiscovery #ArtificialIntelligence #Biotechnology #Innovation

??Check the comments section for the full News link. ?? Merck Life Science Partners with Aragen Bioscience to Advance mAb Manufacturing ???? Merck Life Science has announced a new collaboration with Aragen Bioscience, marking a significant milestone in the biotech sector. The Memorandum of Understanding (MoU), signed by Aditya Sharma, Head of Process Solutions, India Region, Merck Life Science, and Subodh Deshmukh, CEO of Aragen, aims to accelerate the development of monoclonal antibody (mAb) manufacturing and process solutions. This ?? partnership signifies a crucial step in supporting the development of ??groundbreaking therapies and scaling innovations in the biotech landscape. #MerckLifeScience, #MoU, #Aragen, #MoleculesAndBiologics, #LifeSciences, #DrugDiscovery, #AdityaSharma, #SubodhDeshmukh

#BioBDHighlights Bayer Co.Lab Welcomes Three New Biotech Companies in China On December 10, Bayer announced a strategic collaboration with Epigenic Therapeutics, Immunocan Biotech, and Accuredit Therapeutics 锐正基因（苏州）有限公司, welcoming these three biotechnology companies to join the BayerCo.Lab co-creation platform. Through this partnership, the companies will leverage Bayer's global innovation and collaboration network to connect with industry resources worldwide, accelerating breakthroughs in the fields of cellular therapies and #CGT. This collaboration marks an important step in driving innovation and expanding opportunities in the #biopharma sector. #Bayer #BiotechInnovation #CGT #CellTherapy #CoCreation #BIOCHINA2025 #Partnership

#Drugdiscovery is a multidisciplonary effort. #AVITHRAPID brings together a team of highly skilled experts in molecular modeling, structural biology, assay development, toxicity profiling, antiviral drug discovery, animal model testing, and clinical trials. Several partners have successfully worked on the discovery of novel antiviral substances. In addition, one pharma partner has identified a small molecule drug against Zika virus that is ready to enter clinical trials. The unique portfolio of substances ranges from validated hits to pre-clinical candidates with proven in vivo efficacy. To further develop and validate this portfolion the AVITHRAPID consortium will work together in 8 Work Packages (#WPs) which operate as an integrated pre-clinical drug discovery value chain. #antiviral #drugdevelopment #biotech #pharma #innovation #healthcare